The field of ophthalmology has witnessed significant advancements in recent years, with innovations aimed at improving the quality of life for individuals suffering from glaucoma and other eye diseases. One such breakthrough is the Gel Stent, a revolutionary medical device designed to manage intraocular pressure (IOP) effectively. In this blog, we will explore the Gel Stent market, its growth trajectory, and the promising future it holds for ocular health.
Understanding Glaucoma and the Need for Effective Treatment
Glaucoma is a group of eye diseases characterized by elevated IOP, which can lead to optic nerve damage and, ultimately, vision loss if left untreated. The primary goal of glaucoma treatment is to lower IOP to prevent further damage to the optic nerve. Traditionally, this has been achieved through medications, laser therapy, or invasive surgical procedures.
However, these conventional methods have their limitations. Medications can be associated with side effects and compliance issues, while surgical interventions like trabeculectomy and tube shunts are invasive and carry risks. This is where the Gel Stent steps in as a game-changer.
The Gel Stent: A Minimally Invasive Solution
Gel Stents are tiny, biocompatible devices made of hydrogel material. They are designed to be implanted into the eye's drainage system to facilitate the outflow of aqueous humor, thus lowering IOP. This minimally invasive procedure offers several advantages:
1. Safety: Gel Stents are less likely to cause complications compared to traditional surgical methods. They are associated with a lower risk of infection and scarring.
2. Minimally Invasive: The procedure is quick and minimally invasive, often performed in an outpatient setting, reducing patient discomfort and recovery time.
3. Sustainability: Gel Stents are designed to provide long-term IOP control, reducing the need for frequent interventions or medication changes.
Market Growth and Industry Players
The Gel Stent market has experienced rapid growth in recent years, and this trend is expected to continue. Several key factors contribute to the market's expansion:
1. Increasing Incidence of Glaucoma: As the global population ages, the prevalence of glaucoma is rising. This demographic shift is driving the demand for effective glaucoma management options like Gel Stents.
2. Technological Advancements: Ongoing research and development efforts are leading to improvements in Gel Stent design and materials, making them even more effective and safe.
3. Physician Adoption: Eye care specialists are increasingly adopting Gel Stents due to their efficacy and patient-friendly nature.
Promising Future
The Gel Stent market Size is poised for continued growth, offering hope to millions of glaucoma patients worldwide. As technology advances and more clinical data become available, Gel Stents may become the preferred choice for IOP management.
Conclusion
In the realm of ocular health, Gel Stents represent a significant advancement in glaucoma management. Their minimally invasive nature, safety profile, and long-term effectiveness make them a promising solution for patients and healthcare providers alike. As the Gel Stent market continues to expand, it is crucial to stay informed about the latest developments in this field to ensure that individuals suffering from glaucoma receive the best possible care.
Read More….
Pharma Grade Magnesium Trisilicate Market
Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
Dr. Chipde was born and brought up in Aurangabad and completed his medical degree from Dr. B.A.M.
He went to All India Institute of Medical Sciences, New Delhi for his Master’s (surgery) and After completion of his master’s, He Joined M.ch in Urology, from Sanjay Gandhi Postgraduate Institute of medical sciences, Lucknow .Age doesn’t matter, says Dr. SAURABH, as at a very early age he started his courier as Senior Residend Surgeon in A.I.I.M.S, New Delhi.
And then he joined Sri Aurobindo Institute of Medical Sciences Indore as Assistant professor, and currently working as an Associate Doctor in Urology and Renal Transplantation in S.A.I.M.S, IndoreHe is also trained in Fundamental skills of robotic-assisted surgery curriculum (FSRS), from Roswell Park Cancer Institute, Buffalo, New York.
He is the one who performed the First Robotic Prostate Surgery in Central India.Dr.
Saurabh Chipde offers a host of treatments that cater to the various ailments faced by their male and female patients.
Few of the ailments treated here are Urinary Tract Infections (UTI), Incontinence, Male Infertility, Kidney Diseases, Renal Transplantation, Bladder Prolapse, Interstitial Cystitis Or Painful Bladder Syndrome, Kidney and Ureteral Stones, Urethral Stricture and Paediatric Urological Disorders to name a few.
Approximately one in every thousand children develops a urethral stricture, sometimes even when they are still a foetus in the womb.
In order to prevent life-threatening levels of urine from accumulating in the bladder, paediatric surgeons like Gaston De Bernardis at the Kantonsspital Aarau have to surgically remove the affected section of the urethra and sew the open ends of the tube back together again.
It would be less damaging to the kidneys, however, if a stent could be inserted to widen the constriction while the foetus is still in the womb.
Stents have been used to treat blocked coronary vessels for some time now, but the urinary tract in foetuses is much narrower in comparison.
It's not possible to produce stents with such small dimensions using conventional methods, which is why De Bernardis approached the Multi-Scale Robotics Lab at ETH Zurich.
The lab's researchers have now developed a new method that enables them to produce highly detailed structures measuring less than 100 micrometres in diameter, as they report in a recently published journal article.
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.
These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.
Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.
